Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00554216 · ClinicalTrials.gov registry record · Phase 3
Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults
A Phase 3 study of Obesity, sponsored by VIVUS.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,267
- Enrollment target
- 5
- Study locations
NCT00554216: Completed Phase 3 study of Obesity, sponsored by VIVUS.
NCT00554216 is a Phase 3 study of Obesity that has completed, run by VIVUS. The registered enrollment target is 1,267 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (55% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00554216, a Phase 3 study of Obesity, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,267 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of two doses of VI-0521 compared to placebo in treatment of obesity in an adult population with BMI ≥ 35.
Conditions Studied
Interventions
- DRUG VI-0521
- DRUG Placebo matched phentermine/topiramate
Study Locations (5)
California
- Research Site - San Diego
Connecticut
- Research - Ridgefield
North Carolina
- Research Site - Durham
Ohio
- Research Site - Toledo
Texas
- Research Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,267 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
What the finished NCT00554216 record still lists
NCT00554216 is an interventional study that assigns participants to a tested intervention. Its 1,267 participants enrollment target places it among the larger protocols in the corpus, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (55% higher).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which VI-0521 is the first listed.
NCT00554216 lists 5 locations in 5 states (California, Connecticut, North Carolina).
Frequently Asked Questions
What is clinical trial NCT00554216 about?
NCT00554216 is a clinical study titled "Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults". The purpose of this study is to evaluate the efficacy and safety of two doses of VI-0521 compared to placebo in treatment of obesity in an adult population with BMI ≥ 35.
What is the current status of trial NCT00554216?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,267 participants. The study started on 2007-11. Estimated completion is 2009-05.
What conditions does trial NCT00554216 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT00554216?
The interventions under investigation include: VI-0521 (DRUG), Placebo matched phentermine/topiramate (DRUG).
Who is sponsoring clinical trial NCT00554216?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00554216 being conducted?
This trial has 5 study locations across California, Connecticut, North Carolina, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00554216's enrollment target sits among peer trials
1,267 63rd of 1053 higher than 991 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790641 · 1,270 participants · NA
Pathways to Perinatal Mental Health Equity
- NCT06876246 · 1,270 participants · NA
SBIR/ STTR Family Check-up Online
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- NCT03678025 · 1,273 participants · Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia